How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,257 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Dry Eye

Contacts) Consider eye lubricants (e.g. lacrilube) for moderate symptoms (esp. at night), but may blur vision Avoid agents with (e.g. Visine original) Consider s and other agents in refractory to other measures (Restasis) ( ) ( ) Other options in refractory cases Lifitegrast (Xiidra) function-associated antigen-1 (LFA-1) antagonist ophthalmic solution One drop instilled every 12 hours Expensive (>$400/month), with risk of eye irritation, altered es must be out of eye for installation for at least 15 (...) . Epidemiology As many as 30% of over age 50 years old complain of dry, irritated eyes III. Causes Decreased blinking with prolonged reading or driving Chronic exposure to dry, dusty conditions See (e.g. s, s, ) IV. Management ral measures Room humidifiers Take computer breaks Protect eyes from fan Avoid drying, s ( s, s, s) Artificial tears or ointments Preservative-free solutions are preferred (e.g. Refresh Plus), esp. if used more than 4x/day users may try rewetting drops (e.g. Renu rewetting, Blink

2017 FP Notebook

182. Corticosteroids - topical (skin), nose, and eyes

pressure in about 30% of people, leading to corticosteroid-induced glaucoma. May cause corticosteroid-induced cataract if use is prolonged. Should not be used with soft contact lenses — lenses should be removed before instillation of drops, and not worn during the period of treatment. Have I got the right topic? Have I got the right topic? From birth onwards. This CKS topic covers the management of people receiving topical corticosteroids, intranasal corticosteroids, and corticosteroid eye preparations (...) , and triamcinolone) are available over-the-counter for the prevention and treatment of seasonal allergic rhinitis in adults 18 years of age and older. [ ] Eye preparations Eye preparations Corticosteroid eye preparations are available as drops, ointments, ophthalmic suspensions, and Minims® (preservative-free, single-use application packs). Some are also available as compound preparations, containing antibacterials. The corticosteroid eye preparations available in the UK include: Betamethasone (drops

2015 NICE Clinical Knowledge Summaries

183. Changes in central corneal thickness values after instillation of oxybuprocaine hydrochloride 0.4%. (PubMed)

(mean±SD). In each subject, one eye was treated with one drop of oxybuprocaine hydrochloride (HCl) and the fellow eye with one drop of normal saline (control). The SP-3000P CCT readings were first obtained before instillation (baseline) and monitored every 30 s after instillation of each eye drop for a period of 10 min.The mean baseline CCT for oxybuprocaine was 526±23 μm. Ten minutes after, it was 526±24 μm. In the control, the mean CCT was 526±27 μm, 10 min after it was 526±28 μm. The mean (...) variation in CCT measurement was -0.7±3.1 (5.5 to -6.8 μm, 95% CI) for oxybuprocaine and -0.6±4.1 μm (7.5 and -8.6 μm, 95% CI) for the fellow eyes (P>0.05). There was no significant variation among the 20 CCT columns for either oxybuprocaine or the control group (P>0.05 for both).One drop of topical oxybuprocaine 0.4% did not cause a significant change in CCT at up to 10 min following instillation. However, higher differences were observed at 2.30 min and 4.30 min after instillation.Copyright © 2012

2012 Contact lens & anterior eye : the journal of the British Contact Lens Association

184. Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

that contains hyaluronate. Hyaluronate binds water and should help to maintain water on the eye. Objective: We plan to study the time course of possible changes in tear film osmolarity following instillation of an isotonic artificial tear containing hyaluronate. The investigators will use the TearLab, a new clinical instrument that has been developed to quickly and easily measure tear film osmolarity. Understanding how artificial tears affect tear film osmolarity over time can help doctors determine (...) efficacy and dosing schedules. The investigators will test the isotonic hyaluronate (Blink Contacts) artificial tears relative to normal saline solution. Hypothesis: The investigators should be able to measure a decrease in tear osmolarity over time following instillation due to the water-binding effect of hyaluronate artificial tears relative to a control (normal saline solution). Condition or disease Intervention/treatment Phase Dry Eye Drug: Artificial tears Not Applicable Detailed Description

2012 Clinical Trials

185. Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

and Interventions Go to Arm Intervention/treatment Experimental: LE Gel A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears. Drug: LE Gel Single drop of LE Gel 0.5% administered to the study eye on visit 2 Other Name: Lotemax Outcome Measures Go to Primary Outcome Measures : Tear Fluid Levels [ Time Frame: 6 hours ] Following a single dose of LE gel 0.5% administered into the study eye (...) Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2012 Clinical Trials

186. Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome

by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Device: Thealoz Duo Gel and Thealoz Duo eye drops Device: Thealoz Duo eye drops Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Allocation: Randomized Intervention Model: Crossover (...) and then cross over to intervention 2 Device: Thealoz Duo Gel and Thealoz Duo eye drops Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day) Other Name: Intervention 1 Device: Thealoz Duo eye drops Thealoz Duo eye drops during the day (4 to 6 drops per day) Other Name: Intervention 2 Experimental: Patients with dry eye syndrome 2 20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1

2015 Clinical Trials

187. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

for the Treatment of Dry Eye: ARISE-1 Study Start Date : September 2015 Actual Primary Completion Date : June 2016 Actual Study Completion Date : July 2016 Arms and Interventions Go to Arm Intervention/treatment Experimental: High Dose RGN-259 High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4 Thymosin Beta 4 (...) Placebo Comparator: Placebo It is composed of the same excipients as RGN-259 but does not contain Tβ4 Drug: Placebo It is composed of the same excipients as RGN-259 but does not contain Tβ4 Other Name: Vehicle Control Experimental: Low Dose RGN-259 Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4

2015 Clinical Trials

188. A pilot study: the efficacy of virgin coconut oil as ocular rewetting agent on rabbit eyes. (PubMed)

A pilot study: the efficacy of virgin coconut oil as ocular rewetting agent on rabbit eyes. Purpose. An open-label pilot study of virgin coconut oil (VCO) was conducted to determine the safety of the agent as ocular rewetting eye drops on rabbits. Methods. Efficacy of the VCO was assessed by measuring NIBUT, anterior eye assessment, corneal staining, pH, and Schirmer value before instillation and at 30 min, 60 min, and two weeks after instillation. Friedman test was used to analyse any changes (...) (P > 0.05). Conclusion. VCO acts as safe rewetting eye drops as it has shown no significant difference in the measurable parameter compared to commercial brand eye drops and saline. These study data suggest that VCO is safe to be used as ocular rewetting agent on human being.

Full Text available with Trip Pro

2015 Evidence-based Complementary and Alternative Medicine (eCAM)

189. Immediate Effects of 3% Diquafosol and 0.1% Hyaluronic Acid Ophthalmic Solution on Tear Break-Up Time in Normal Human Eyes. (PubMed)

Immediate Effects of 3% Diquafosol and 0.1% Hyaluronic Acid Ophthalmic Solution on Tear Break-Up Time in Normal Human Eyes. The purpose of this study was to evaluate the immediate effect of 3% diquafosol ophthalmic solution on tear break-up time (TBUT) in normal human eyes, and to compare it with that of saline and 0.1% hyaluronate ophthalmic solution.Cross sectional comparative study in the first study, 10 healthy volunteers underwent topical application of 2 different ophthalmic solutions (...) in each eye. Saline was randomly applied to one eye and 3% diquafosol ophthalmic solution was added to the fellow eye. TBUT was measured and video recorded before application and at 5, 10, 15, and 20 min after. The TBUT in each eye was compared at each time point with regard to the 2 different ophthalmic solutions. In the second study, another 10 healthy volunteers were included. The same methods were used to compare the immediate effects of 0.1% hyaluronate and 3% diquafosol ophthalmic solution

2015 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

190. Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye

Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the clinical benefits of SYSTANE® ULTRA Lubricant Eye Drops using total ocular surface staining scores in subjects with dry eye administering it either as a scheduled regimen or as-needed after 28 days of treatment. Condition or disease Intervention/treatment Phase Dry Eye Syndrome Drug: SYSTANE® ULTRA Lubricant Eye Drops Not Applicable Detailed (...) Description: This study consists of a 14-day Run-in Phase (between the Screening Visit and Baseline/Visit 1) and a Treatment Phase. During the Run-in Phase, subjects will discontinue current artificial tears and will be dispensed SYSTANE® ULTRA to be administered 1 drop in each eye as needed (PRN). Subjects who meet the re-evaluation criteria after the Run-in Phase will be randomized in a 1:2 manner to receive treatment with SYSTANE® ULTRA 4 times per day (QID) or PRN, respectively, for 28 days. Study

2015 Clinical Trials

191. Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate (PubMed)

test), tear film breakup time (TBUT), corneal staining and tear osmolarity were assessed. Fucosyl-lactose eye drops was instilled at different concentrations (0.01, 0.1, and, 1%).After 24 h from first atropine administration, tear volume and TBUT values were significantly improved in groups treated with 2-fucosyl-lactose in a dose-dependent manner. Tear volume increased from 5.25 to 10.75 mm and TBUT values from 8.75 to 34.5 s with 0.01% or 1% 2-fucosyl-lactose treatment, respectively. No changes (...) Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate Colostrum has been proposed to treat severe dryness and problematic eye lesions showing a beneficial effect. The aim of the study was to investigate the effect of 2-fucosyl-lactose, a natural sugar present in the human colostrum, in an experimental dry eye.Dry eye was induced in adult male New Zealand albino rabbits by topical administration of 1% atropine. Tear volume (Schirmer's

Full Text available with Trip Pro

2015 Frontiers in pharmacology

192. Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye (PubMed)

of the eye. Immunoactivities gradually diminished at 3 and 6 h after the final eye drop. Quantitative estimations of the amount of peptide in the retina were 15.3, 5.8 and 1.0 pg/μg protein at 1, 3 and 6 h after the final instillation, respectively. Current results suggest that while the topically applied Tat-μCL peptide reaches the posterior segment of the retina and the optic nerve, the sufficient concentration (> IC50) is maintained for at least 6 h in the rat retina. Our findings suggest (...) topical application in adult rats. Distribution of the peptide was determined by immunohistochemical analysis, and enzyme-linked immune-absorbent assay was used to quantify the accumulation in the retina. Peptides were prominently detected in both the anterior and posterior segments of the eye at 1 h after the final eye drop application. Immunohistochemically positive reactions were observed in the retina, optic nerve, choroid, sclera and the retrobulbar tissues, even in the posterior portion

Full Text available with Trip Pro

2015 PloS one

193. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. (PubMed)

Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. This study was designed to investigate the effect of a single-drop instillation of different lacrimal substitutes on tear film thickness (TFT) assessed with optical coherence tomography in patients with mild to moderate dry eye disease.The study was performed in a randomized, double-masked, controlled parallel group design. Patients received a single dose of either unpreserved trehalose 30 mg/mL (...) and sodium hyaluronate 1.5 mg/mL (TH-SH, Thealoz Duo), unpreserved sodium hyaluronate, 0.15% (HA, Hyabak) or sodium chloride, 0.9% (NaCl, Hydrabak) eye drops. Sixty patients finished the study according to the protocol. TFT was measured with a custom-built ultrahigh-resolution Fourier domain optical coherence tomography system providing a resolution of 1.2 μm.The mean TFT before treatment was 2.5 ± 0.4 μm. Ten minutes after instillation, TFT significantly increased in the TH-SH group from 2.4 ± 0.4

2015 Cornea

194. A Pilot Study: The Efficacy of Virgin Coconut Oil as Ocular Rewetting Agent on Rabbit Eyes (PubMed)

A Pilot Study: The Efficacy of Virgin Coconut Oil as Ocular Rewetting Agent on Rabbit Eyes Purpose. An open-label pilot study of virgin coconut oil (VCO) was conducted to determine the safety of the agent as ocular rewetting eye drops on rabbits. Methods. Efficacy of the VCO was assessed by measuring NIBUT, anterior eye assessment, corneal staining, pH, and Schirmer value before instillation and at 30 min, 60 min, and two weeks after instillation. Friedman test was used to analyse any changes (...) (P > 0.05). Conclusion. VCO acts as safe rewetting eye drops as it has shown no significant difference in the measurable parameter compared to commercial brand eye drops and saline. These study data suggest that VCO is safe to be used as ocular rewetting agent on human being.

Full Text available with Trip Pro

2015 Evidence-based Complementary and Alternative Medicine : eCAM

195. Eyedrop Instillation Technique

Details Study Description Go to Brief Summary: Eye drop instillation is a problem from glaucoma patients. Studies reveal that 30-50% of glaucoma patients have problems instilling their eyedrops. These problems include not hitting the eye, spending many drops to get a single successful instillation and bottle contamination. The present study will evaluate the effect of encouraging patients to put their eyedrops using one of 2 techniques, randomly assigned, to determine which is more successful (...) at instilling the eye drop into the eye while spending the least amount of drug. In one of the techniques the patient instills the eye drop with their eyes open in the inferior cul de sac. In the other technique the patient instills the eye drop with the eyes closed near the inner canthal region. Patients will be randomized to encouragement to use the drops with either of the techniques. Encouragement will take place over a visit where they will be subjected to: Baseline evaluation of eye drop instillation

2011 Clinical Trials

196. Effects of sodium hyaluronate on wavefront aberrations in dry eye patients. (PubMed)

Effects of sodium hyaluronate on wavefront aberrations in dry eye patients. To investigate the effects of a single instillation of hypotonic 0.18% sodium hyaluronate artificial tears on wavefront aberrations in dry eye patients.Fifty patients with dry eye were recruited into this single-center, prospective, double-masked, randomized controlled trial. Patients were randomly assigned to receive one drop of preservative-free, hypotonic 0.18% sodium hyaluronate (treatment) in one eye and one drop (...) of sterile 0.9% sodium chloride solution (control) in the other eye. Ocular aberrations evaluated by a Hartmann-Shack aberrometer and severity of dry eye symptoms graded by a questionnaire (at baseline, 1, 10, 30, 60, and 120 minutes after instillation) were the main outcome measures.After a single instillation of one drop of the allocated eye drops, there were no statistically significant differences between the treatment and control groups in total higher-order aberrations, coma, and spherical

Full Text available with Trip Pro

2014 Optometry and vision science : official publication of the American Academy of Optometry

197. A Novel OCT technique to Measure in vivo the Corneal Adhesiveness for Sodium Carboxymethylcellulose in Humans and its validity in the Diagnosis of Dry Eye. (PubMed)

significant intraclass correlation (ICC) value of 0.99 was found for measurements of corneal adhesiveness on two subsequent days at the same time (P < 0.001).This minimally invasive, novel technique of OCT imaging of the corneal surface following NaCMC drop instillation provides a measure of corneal adhesiveness. This technique may improve the clinician's ability in the understanding and diagnosis of the dry eye syndrome.Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. (...) A Novel OCT technique to Measure in vivo the Corneal Adhesiveness for Sodium Carboxymethylcellulose in Humans and its validity in the Diagnosis of Dry Eye. The purpose of this work was to gather preliminary data on tear film stability, and the adhesive properties of the corneal surface in dry eye patients and control group subjects, using a new, minimally invasive optical coherence tomography (OCT) imaging method.We screened 85 human subjects for dry eye and classified them in two groups

Full Text available with Trip Pro

2014 Investigative Ophthalmology & Visual Science

198. Effects of Benzalkonium Chloride on the Blood-Aqueous and Blood-Retinal Barriers of Pseudophakic Eyes. (PubMed)

Effects of Benzalkonium Chloride on the Blood-Aqueous and Blood-Retinal Barriers of Pseudophakic Eyes. To evaluate the effects of benzalkonium chloride (BAK) on the blood-aqueous (BAB) and blood-retinal barriers (BRB) of pseudophakic eyes.Prospective, randomized, investigator-masked, comparative study. Patients were randomly assigned to preservative-free artificial tears or BAK-preserved artificial tears. One drop of artificial tears was instilled 4 times a day in the study eye, starting (...) the day after randomization for 30 days. Anterior chamber flare was assessed by a laser flare meter (LFM) and macular thickness measurements were obtained with optical coherence tomography, before, 15, and 30 days after randomization.A total of 44 healthy eyes of 44 pseudophakic volunteers were recruited. There were no significant differences regarding demographics (age, gender, and race distributions) and clinical characteristics (eye, mean intraocular pressure, and mean best-corrected visual acuity

2014 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

199. Prospective, randomized, contralateral eye comparison of tetracaine and proparacaine for pain control in laser in situ keratomileusis and photorefractive keratectomy. (PubMed)

-masked, randomized study comprised 256 eyes from 128 consecutive patients being treated with LASIK or PRK who were randomized to receive tetracaine in one eye and proparacaine in the other. The patients were blinded as to which anesthetic agent was used in each eye. Pain levels were graded on a 0-10 scale, and were assessed upon instillation, during surgery, immediately postoperatively, 30 minutes postoperatively, overnight, and on postoperative day 1. Patients were asked 30 minutes after surgery (...) which anesthetic agent they would choose.Both anesthetic agents resulted in diminished amounts of subjective pain in patients undergoing LASIK and PRK. Tetracaine caused significantly more pain upon instillation than proparacaine for both LASIK and PRK patients. LASIK patients noted significantly less pain 30 minutes after surgery when treated with tetracaine. Significantly more LASIK patients preferred the eye treated with tetracaine. These differences were not present in the PRK group.Both

Full Text available with Trip Pro

2014 Clinical ophthalmology (Auckland, N.Z.)

200. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - A randomised comparative study. (PubMed)

] and for the Van Bijsterveld score [CE: -1.4 ± 1.2; PVA-P: -0.9 ± 1.2; P=0.046] in the CE group. The same applied for the palpebral erythema score (P=0.023), overall efficacy assessed by the investigators (P<0.001), and symptoms not related to eye drop instillation (P=0.021). Improvement was observed from D7. No difference was observed between the two treatments with regard to ocular safety.These results suggest that in patients with mild to moderate dry eye, Cationorm, in addition to its moisturizing (...) objective criteria were assessed to compare the two eye drops: tear Break-up Time (TBUT), Schirmer's test, lissamine green staining (Van Bijsterveld score), corneal fluorescein staining (Oxford scale) and oculopalpebral examination, on D7 and D28 (end of study). At these visits, ocular symptoms and safety were also assessed.Seventy-nine patients were randomised: CE: 44 patients; PVA-P: 35 patients. At D28, improvement was significantly better for TBUT [CE: 1.7 ± 2.4 s; PVA-P: 0.6 ± 1.8 s; P=0.015

2014 Journal français d'ophtalmologie

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>